NCT02195180 - Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma | Biotech Hunter

Enrollment

141

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

February 28, 2017

Study Completion Date

November 30, 2017

Conditions

Pancreatic Adenocarcinoma Metastatic

Interventions

DRUG

ERY001

DRUG

Gemcitabine

DRUG

5-fluoro-uracil/oxaliplatin/leucovorin (folfox)

oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2

Trial Locations (16)

29609

Institut de Cancerologie, Brest

31059

CHU Toulouse - Rangueil, Toulouse

34298

Institut Regional du Cancer-Montpellier Val d'Aurelle, Montpellier

37044

CHU de Tours, Tours

38028

Groupe Hospitalier Mutualiste Grenoble, Grenoble

42109

CHU de Poitiers, Poitiers

51100

CHU Reims, Reims

59020

Centre Oscar Lambret, Lille

69373

Cnetre Leon Berard, Lyon

75014

Institute Mutualiste Montsouris, Paris

75571

Hospital Saint Antoine, Paris

75651

Hospital Pitie Salpetriere, Paris

84918

Saint Catherine Institute, Avignon

85925

Centre Hospitalier Departemental Vendee - Les Oudairies, La Roche-sur-Yon

92118

Hopital Beaujon, Clichy

94010

Hospital Henri Mondor, Créteil